A Randomized Patient Preference Trial on Heat-sensitive Moxibustion for Primary Hypertension in Community

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

400 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-03-10

Study Completion Date

2021-12-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Heat-sensitive moxibustion, an important mean of external therapy of traditional Chinese medicine, has unique advantages in treating various chronic diseases than common moxibustion. This study aims to evaluate the efficacy, safety, and cost-effectiveness of heat-sensitive moxibustion for primary hypertension under community self-management setting using a multicenter, pragmatic, randomized controlled trial design with patient-preference arms.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Heat-sensitive Moxibustion Self-administration in Patients in the Community With Primary Hypertension: Protocol for a Multi-center, Pragmatic, Non-randomized Trial

NCT04381520

Primary Hypertension

UNKNOWN NA

Effect of Acupuncture on Patients With Mild Hypertension

NCT01701726

Essential Hypertension

COMPLETED PHASE3

Exploring the Effect of Combined Chinese and Western Treatment on Home Medical Care

NCT03600220

Hypertension

UNKNOWN NA

Moxibustion for Primary Dysmenorrhea

NCT01972906

Primary Dysmenorrhea

COMPLETED EARLY_PHASE1

The Moxibustion-Induced Thermal Transport Effect Between The Heart And Lung Meridians

NCT05330403

Meridians

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary hypertension is a common chronic disease that threatens the life and health of human beings. The conventional western drug therapy often has side effects and many patients are unable to achieve ideal blood pressure control with drugs alone. Therefore, the treatment of primary hypertension still requires active exploration of complementary and alternative therapies with clear clinical efficacy.

Heat-sensitive moxibustion is an innovative moxibustion therapy. By stimulating the patient's special moxibustion sensation, heat-sensitive moxibustion can achieve better results than traditional moxibustion for many diseases, including primary hypertension. Heat-sensitive moxibustion is an easy, inexpensive and safe treatment method. The practitioner does not need to be professionally qualified to perform moxibustion, making it a suitable technique for patients to self-medicate on a daily basis. Traditional moxibustion has been shown to lower blood pressure in patients with primary hypertension. Theoretically, heat-sensitive moxibustion could achieve better blood pressure lowering effects, but its effects in lowering blood pressure in the setting of self-management in community patients is unclear. To verify the efficacy and safety of heat-sensitive moxibustion community self-management for hypertension, we plan to perform a randomized controlled trial. In this trial, we designed the trial grouping scheme as a randomized controlled trial with patient preference arms in order to improve patient adherence and reduce the impact of patient preference effects.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized controlled trial with patient preference arms

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Data analysts will be blinded.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Heat-sensitive moxibustion group A

In this group, patients are compulsively randomized to receive heat-sensitive moxibustion. They will maintain their original antihypertensive treatment (antihypertensive drugs or no treatment).

Group Type EXPERIMENTAL

Heat-sensitive moxibustion plus original antihypertensive treatment (compulsively randomized arm)

Intervention Type OTHER

In this group, patients will self-administer heat-sensitive moxibustion or have family members help with the administration for six months. During this period, they will maintain their original antihypertensive treatment.

Control group A

In this group, patients are compulsively randomized to not receive heat-sensitive moxibustion. They will maintain their original antihypertensive treatment (antihypertensive drugs or no treatment).

Group Type ACTIVE_COMPARATOR

Original antihypertensive treatment (compulsively randomized arm)

Intervention Type DRUG

In this group, patients will maintain their original antihypertensive treatment.

Heat-sensitive moxibustion group B

Patients who voluntarily choose to receive randomization and are randomly assigned to receive heat-sensitive moxibustion. They will maintain their original antihypertensive treatment (antihypertensive drugs or no treatment).

Group Type EXPERIMENTAL

Heat-sensitive moxibustion plus antihypertensive treatment (voluntarily randomized arm)

Intervention Type OTHER

In this group, patients will self-administer heat-sensitive moxibustion or have family members help with the administration for six months. During this period, they will maintain their original antihypertensive treatment.

Control group B

Patients who voluntarily choose to receive randomization and are randomly assigned to not receive heat-sensitive moxibustion. They will maintain their original antihypertensive treatment (antihypertensive drugs or no treatment).

Group Type ACTIVE_COMPARATOR

Original antihypertensive treatment (voluntarily randomized arm)

Intervention Type DRUG

In this group, patients will maintain their original antihypertensive treatment.

Heat-sensitive moxibustion group C

Patients who voluntarily choose to receive heat-sensitive moxibustion. They will maintain their original antihypertensive treatment (antihypertensive drugs or no treatment).

Group Type EXPERIMENTAL

Heat-sensitive moxibustion plus original antihypertensive treatment (preference selection arm)

Intervention Type OTHER

In this group, patients will self-administer heat-sensitive moxibustion or have family members help with the administration for six months. During this period, they will maintain their original antihypertensive treatment.

Control group C

Patients who voluntarily choose to not receive heat-sensitive moxibustion. They will maintain their original antihypertensive treatment (antihypertensive drugs or no treatment).

Group Type ACTIVE_COMPARATOR

Original antihypertensive treatment (preference selection arm)

Intervention Type DRUG

In this group, patients will maintain their original antihypertensive treatment.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Heat-sensitive moxibustion plus original antihypertensive treatment (compulsively randomized arm)

In this group, patients will self-administer heat-sensitive moxibustion or have family members help with the administration for six months. During this period, they will maintain their original antihypertensive treatment.

Intervention Type OTHER

Original antihypertensive treatment (compulsively randomized arm)

In this group, patients will maintain their original antihypertensive treatment.

Intervention Type DRUG

Heat-sensitive moxibustion plus antihypertensive treatment (voluntarily randomized arm)

In this group, patients will self-administer heat-sensitive moxibustion or have family members help with the administration for six months. During this period, they will maintain their original antihypertensive treatment.

Intervention Type OTHER

Original antihypertensive treatment (voluntarily randomized arm)

In this group, patients will maintain their original antihypertensive treatment.

Intervention Type DRUG

Heat-sensitive moxibustion plus original antihypertensive treatment (preference selection arm)

In this group, patients will self-administer heat-sensitive moxibustion or have family members help with the administration for six months. During this period, they will maintain their original antihypertensive treatment.

Intervention Type OTHER

Original antihypertensive treatment (preference selection arm)

In this group, patients will maintain their original antihypertensive treatment.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Diagnosed with essential hypertension, i.e., systolic blood pressure ≥ 140mmHg and/or diastolic blood pressure ≥ 90 mmHg, with a course more than 6 months.
2. Ages: 18-80 years;
3. The original antihypertensive drugs are calcium channel blockers and/or angiotensin II receptor blockers.
4. Did not receive acupoint stimulation therapies for hypertension in the last month.
5. Patients in the heat-sensitive moxibustion groups need to develop at least one type of moxibustion sensation around the following acupoints: Yongquan, Baihui, Shenque, Quchi, Zusanli, Hegu, Taichong and Dazhui.
6. Consent to sign an informed consent form

Exclusion Criteria

1. Systolic blood pressure ≥ 180mmHg and/or diastolic blood pressure ≥ 110mmHg after taking antihypertensive drugs;
2. Secondary hypertension.
3. Pregnancy and lactation;
4. Allergic to moxibustion devices, moxa smoke or Artemisia argyi.
5. Complicated with severe diseases that are not recommended for heat-sensitive moxibustion, such as acute cerebral hemorrhage, hypertensive crisis, sensory disturbances, serious mental diseases, etc.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No